Murine Dermal Fibroblast Isolation by FACS

Summary

Fibroblast behavior underlies a spectrum of clinical entities, but they remain poorly characterized, largely due to their inherent heterogeneity. Traditional fibroblast research relies upon in vitro manipulation, masking in vivo fibroblast behavior. We describe a FACS-based protocol for the isolation of mouse skin fibroblasts that does not require cell culture.

Abstract

Fibroblasts are the principle cell type responsible for secreting extracellular matrix and are a critical component of many organs and tissues. Fibroblast physiology and pathology underlie a spectrum of clinical entities, including fibroses in multiple organs, hypertrophic scarring following burns, loss of cardiac function following ischemia, and the formation of cancer stroma. However, fibroblasts remain a poorly characterized type of cell, largely due to their inherent heterogeneity. Existing methods for the isolation of fibroblasts require time in cell culture that profoundly influences cell phenotype and behavior. Consequently, many studies investigating fibroblast biology rely upon in vitro manipulation and do not accurately capture fibroblast behavior in vivo. To overcome this problem, we developed a FACS-based protocol for the isolation of fibroblasts from the dorsal skin of adult mice that does not require cell culture, thereby preserving the physiologic transcriptional and proteomic profile of each cell. Our strategy allows for exclusion of non-mesenchymal lineages via a lineage negative gate (Lin^-) rather than a positive selection strategy to avoid pre-selection or enrichment of a subpopulation of fibroblasts expressing specific surface markers and be as inclusive as possible across this heterogeneous cell type.

Introduction

Fibroblasts are frequently defined morphologically as spindle-shaped cells that adhere to plastic substrates. Fibroblasts are the principle cell type responsible for synthesizing and remodeling the extracellular matrix in embryonic and adult organs¹. Fibroblasts are thus critical to mammalian development and contribute substantially to the extracellular milieu that influences the behavior of neighboring cell types present in each tissue and organ.

Fibroblasts are also the principal cell type behind a diverse set of medical conditions that cause enormous clinical burden. Pathologic fibroblast activity impairs normal tissue function and includes tissue and organ fibrosis (such as the lung and liver), scarring following cutaneous wound healing, atherosclerosis, systemic sclerosis, and formation of atheromatous plaques after blood vessel injury^2-5. Wound healing in particular, both acutely and chronically, involves deposition of scar tissue that neither resembles nor functions like the normal tissue surrounding it, and leads to significant morbidity across diverse pathologic states. Following injury, there is a transition of fibroblasts to myofibroblasts, which then secrete structural ECM components, exert paracrine effects on neighboring cell types, and restore mechanical stability by depositing scar tissue⁶.

In cutaneous tissues there exists significant variation in the quality of wound repair across developmental time and between anatomic sites. In the first two trimesters of life the fetus heals without scarring; however, from the third trimester on and throughout adulthood, humans heal with a scar. Site-specific, in addition to age-specific, differences in wound healing exist. Wounds in the oral cavity remodel with minimal scar formation^7,8, while scar tissue deposition within cutaneous wounds is significant⁹. Controversy persists concerning the relative influence of the environment versus the intrinsic properties of local fibroblasts on the outcome of wound healing in regards to both age and location^10,11. Given the significant differences in the healing of mouse oral vs. cutaneous dermis and earlier embryonic (E15) vs. later embryonic (E18) dermis, it is likely that intrinsic differences in the populations of fibroblasts at certain developmental ages and among various anatomic sites exist.

In 1986, Harold F. Dvorak posited tumors are wounds that do not heal¹². Dvorak concluded that tumors behave like wounds in the body and induce their stroma by activating the wound healing response of the host. Numerous studies have since investigated the contribution of fibroblasts to the progression of carcinomas^13-15, but as in the case of wound healing, the identity and embryonic origin of the fibroblasts that contribute to the stromal compartment of cutaneous carcinomas has not been adequately defined. The answer to this question bears medical relevance given recent studies exposing the tumor-associated fibroblast as a potentially effective target for anti-cancer therapy¹⁶.

Identifying and prospectively isolating the fibroblast lineages endowed with fibrogenic potential in vivo is an essential step towards effectively manipulating their response to injury across a wide range of acute and chronic disease states. In 1987, Cormack demonstrated two subpopulations of fibroblasts, one residing within the papillary and one within the reticular dermis^17,18. A third subpopulation was found associated with hair follicles in the dermal papilla region of the follicle^19,20. When cultured, these fibroblast subtypes exhibit differences in growth potential, morphology, and growth factor/cytokines profiles^21-24.

To date, studies examining fibroblast heterogeneity have largely failed to adequately characterize developmental and functional diversity among fibroblasts in vivo. This is, in part, is a result of a reliance on cultured fibroblast populations and the homogenizing effect of cell culture or positive selection on the basis of a self surface receptor not expressed by all fibroblasts²⁵. A recent study from our lab demonstrated a profound surface marker and transcriptional shift in cultured vs. uncultured fibroblasts isolated by the FACS-based isolation methodology presented in this manuscript²⁶.

Subsequently, we identified a specific fibroblast lineage within the murine dorsal dermis and determined that this lineage, defined by embryonic expression of Engrailed-1, is primarily responsible for connective tissue deposition in the dorsal skin. The lineage functions during both acute and chronic forms of fibrosis including wound healing, cancer stroma formation, and radiation induced fibrosis²⁷. The characterization of distinct fibroblast lineages has critical implications for therapies aimed at modulating fibrogenic behavior.

Rather than using existing protocols that rely upon in vitro manipulation to achieve cell isolation^28,29, the harvest protocol (Figure 1) detailed here will help yield informative analyses of fibroblasts that more accurately capture phenotype and behavior in vivo.

Protocol

This protocol follows methods approved by the Stanford University Administrative Panel on Laboratory Animal Care.

1. Digestion of Murine Dermis

1. Euthanize mice by cervical dislocation after anesthesia with an intraperitoneal injection of ketamine 100 mg/kg + xylazine 20 mg/kg + acepromazine 3 mg/kg.
   Note: Various ages and backgrounds can be used.
2. Shave and depilate the dorsal skin. Approximately 100,000 cells can be isolated from a piece of dorsal skin 60 mm x 100 mm.
3. Submerge the mouse in 70% ethanol and place on a clean, sterile surface to dry.
4. Immediately harvest dorsal mouse skin using sterile dissecting scissors. In female mice, avoid including the mammary tissue.
5. Starting the base of the tail, use forceps to tent up the skin and make a transverse cut before dissecting along the supra-fascial plane.
6. Carefully avoid including any subcutaneous fat while harvesting the skin. Examine the harvested skin for any subcutaneous fat and carefully scrape it off using the blunt edge of a scalpel.
7. Rinse the harvested skin in betadine followed by 5x PBS washes on ice.
   Note: It is important to keep the skin as close to sterile as possible to avoid contamination.
8. Mince the skin using razor blades and dissecting scissors in a sterile dish until the sample is of a uniform consistency with 2-3 mm pieces.
9. Prepare 50 ml conical tubes containing 20 ml collagenase IV at a concentration of 1 mg/ml in DMEM. Divide the dermis into the tubes on the basis of five mice per tube.
10. Agitate samples vigorously while incubating at 37 °C for 1 hr in either a water bath or oven.
11. Remove samples from the incubator and pass through a 10 ml syringe without a needle 3-5x in a sterile hood.
12. Place the samples back into the incubator at 37 °C and shake vigorously for a further 30 min.
13. In a sterile hood, pipette the samples up and down 3-5x using a 10 ml pipette. Pipette the sample through a 100 µm filter into a new 50 ml conical tube.
14. Pass 20 ml of 10% FBS DMEM through the same filter to maximize cell yield and bring the total volume to 40 ml. Centrifuge at 300 g for 8 min at 4 °C.
15. Remove the supernatant using a sterile glass pipette, taking great care to first remove the upper fat layer prior to remaining supernatant.
    Note: This step is critical to reduce adipocyte contamination.
16. Resuspend the pellets in 20 ml 10% FBS DMEM.
17. Pass the cell/DMEM suspension through a 70 µm filter.
18. Rinse the filter with 10 ml 10% FBS DMEM and centrifuge the filtered suspension at 300 g for 8 min at 4 °C.
19. Remove the supernatant using a sterile glass pipette, again taking care to first remove any remaining fat layer.
20. If there is significant RBC contamination (the pellet is visibly red), re-suspend the pellets in 20 ml ACK lysis buffer and incubate for 5 min at RT. Otherwise skip to step 24.
21. Add an equal volume (20 ml) of FACS buffer (PBS, 10% FBS, 0.1% sodium azide), then mix, and keep aside a 5 ml aliquot as an unstained control. Centrifuge the remaining sample at 300 g for 8 min at 4 °C.
22. Remove supernatant and put pellet on ice. The cells may be frozen down at this point if FACS time is not available.

2. Isolation of Fibroblasts by FACS

1. Make 500 µl of lineage antibody incubation mix for each pellet. Do this by first adding 475 µl of FACS buffer containing DNase (10 µg/ml) to a tube, and then adding fluorophore-conjugated CD31 (1:100), CD45 (1:200), Tie2 (1:50), Ter-119 (1:200), and EpCAM (1:100) antibodies to achieve the respective dilution for each antibody.
2. Re-suspend each pellet in 500 µl of lineage antibody incubation mix and incubate this suspension on ice for 20 min.
3. Add 5 ml FACS buffer containing DNase (10 µg/ml) to the sample and gently mix. Centrifuge at 300 g for 8 min at 4 °C.
4. Remove the supernatant and wash the cell pellet with 5ml FACS buffer containing DNase (10 µg/ml) and centrifuge using the same conditions as in step 26.
5. Resuspend the pellet in 500 µl FACS buffer containing DNase (10 µg/ml) and put aside a 50 µl aliquot as a viability dye control.
6. Add viability dye of choice to the remaining sample in the concentration indicated for the chosen dye.
7. Perform FACS analysis³¹ and sorting for Viability Dye-/CD31-/CD45-/Tie2-/Ter-119-/EpCAM- cells (see Figure 2A). Sort directly into FACS buffer.

Results

The validity of this approach (Figure 1) has been verified in a number of ways, which can be examined in detail in our recent publication²⁷. These include immunocytochemistry of sorted cells and mass cell and single cell transcriptional analysis of freshly sorted cells. Sorting fibroblasts directly rather than relying on culture more accurately captures their in vivo phenotype. Using a lineage negative depletion approach (Figure 2A) rather than a positive selection approach avoids pre-sel...

Discussion

The protocol described in this manuscript offers a means to isolate fibroblasts by FACS-based sorting, in comparison to existing methods, which either select for a subpopulation or require time in cell culture before subsequent analyses. The time required from harvesting of the skin to sorting of fibroblasts is approximately 6 hr; however, the number of mice used in the harvest will influence this estimate.

Several points in the protocol require particular care. The first is limiting adipocyte...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Surgical Forceps	Kent Scientific	INS650916
Micro-scissors	Kent Scientific	INS600127
Povidone Iodine Prep Solution	Dynarex	1415
Nair (depilatory cream)	Church and Dwight Co.	22600267058
Collagenase IV	Gibco	17104-019
Elastase	Abcam	ab95133
DMEM	Life Technologies	A14430-01
Fetal Bovine Serum	Gibco	16000-044
Ammonium-Chloride-Potassium (ACK) lysing buffer	Gibco	A10492-01
40 μm filters	Fisher Scientific	08-771-1
70 μm filters	Fisher Scientific	08-771-2
100 μm filters	Fisher Scientific	08-771-19
CD31	BioLegend	102421
CD45	BioLegend	103125
Tie2	BioLegend	124005
Ter-119	BioLegend	116233
EpCAM (CD326)	eBioscience	48-5791
DAPI	Invitrogen	D3571
propidium iodide (PI viability stain)	BioLegend	421301